Roche's anti-TIGIT drug, tiragolumab, failed to demonstrate a life-extending benefit in a Phase 3 trial for non-small cell lung cancer, raising concerns about the TIGIT inhibitor class.
AbbVie's tavapadon met its primary endpoint in the TEMPO-2 Phase 3 trial, demonstrating significant improvement in Parkinson's disease symptoms and quality of life.